Mazor Robotics (MZOR)

[nuketheshorts]

Mazor Robotics’ Renaissance Technology Receives Health Canada License



CAESAREA, Israel – January 28, 2013 – Mazor Robotics Ltd. (TASE: MZOR), a developer of innovative surgical robots and complementary products, today announced the Company received its Health Canada (HC) Medical Device License to market its Renaissance system and accompanying accessories in Canada.



The HC license encompasses Renaissance use in both spine and brain applications, subject to specifications outlined in the clearance documents. The company plans to begin marketing the Renaissance technology through distributor partnerships in 2013.



“The receipt of the HC license is an important step in securing our foothold in North America,” stated Ori Hadomi, CEO. “We made significant progress expanding in the U.S. in 2012, and we have begun 2013 with the intent to further our growth and bring our innovative technology to new markets. Canada is a key geography for spine and brain applications, and we are excited to provide our Renaissance technology to the patients of Canada.”



Renaissance, Mazor Robotics’ next generation surgical guidance system for spine procedures, is transforming spine surgery from freehand operations to highly-accurate, state-of-the-art procedures, with less radiation – even for minimally invasive surgery, scoliosis, and other complex spinal deformity cases. It is the only robotic technology for spine surgery available in the marketplace.


About Mazor

Mazor Robotics (TASE:MZOR) is dedicated to the development and marketing of innovative surgical robots and complementary products that provide a safer surgical environment for patients, surgeons, and operating room staff. Mazor Robotics’ flagship product, Renaissance™, is a state-of-the-art surgical robotic system that enables surgeons to conduct spine surgeries in an accurate and secure manner. Mazor Robotics systems have been successfully used in the placement of over 35,000 implants in the United States and Europe. Numerous peer-reviewed publications and presentations at leading scientific conferences have validated the accuracy, usability, and clinical advantages of Mazor Robotics technology. For more information, please visit www.mazorrobotics.com.



U.S. Contacts: EVC Group



Aimee Gordon/Robert Jones-- Investors

[e-mail]/bjones

212/850-6020; 646/201-5447



Chris Gale—Media

[e-mail]

646/201-5431